Compare EZGO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | VRAX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.3M |
| IPO Year | 2020 | 2021 |
| Metric | EZGO | VRAX |
|---|---|---|
| Price | $1.01 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 77.8K | ★ 486.8K |
| Earning Date | 07-01-2025 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.10 |
| 52 Week High | $3.30 | $13.19 |
| Indicator | EZGO | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 55.43 |
| Support Level | $0.88 | $0.19 |
| Resistance Level | $1.33 | $4.75 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 29.24 | 31.65 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.